What is the level of liabilities of Karo Pharma this year?
Karo Pharma has a debt balance of 6.78 B SEK this year.
Karo Pharma Liabilities 2024
Karo Pharma Liabilities
6.78 B SEK
Ticker
KARO.ST
ISIN
SE0007464888
WKN
A14YW4
In 2024, Karo Pharma's total liabilities amounted to 6.78 B SEK, a 0% difference from the 0 SEK total liabilities in the previous year.
Karo Pharma Aktienanalyse
What does Karo Pharma do?
Karo Pharma AB is a Swedish pharmaceutical company specializing in the manufacturing and distribution of over-the-counter drugs and health products. The company's history dates back to 1986 when it was founded as Karo Bioforskning. Over time, the company went through several restructurings and realignments until it finally became an independent company listed on the Stockholm Stock Exchange in 2017 under the name Karo Pharma AB. Karo Pharma's business model is based on a broad portfolio of over-the-counter drugs and health products tailored to the needs of consumers in different countries and for different indications. The product range includes pain relievers, cold remedies, medications for digestive disorders, and eye care products. In addition, the company also offers dietary supplements and other health products. Karo Pharma operates in three main segments: Consumer Healthcare, Prescription Pharmaceuticals, and Out-licensing. Consumer Healthcare focuses on over-the-counter drugs and health products for end consumers. Examples include VagiVital, a medication for the treatment of vaginal yeast infections, and MolluscumVital, a product for the removal of warts. In the Prescription Pharmaceuticals segment, Karo Pharma offers prescription drugs for specific indications, such as Eklira, used in the treatment of chronic obstructive pulmonary disease (COPD). The Out-licensing segment involves the licensing of products and technologies to other companies. Karo Pharma has a particular focus on the development of products based on natural active ingredients. For example, Prenoxdiazin, used for pain relief, is based on an extract from the root of peonies. Natural ingredients are preferred in the development of other products as well, to maximize their compatibility and effectiveness. Overall, Karo Pharma's portfolio includes more than 20 brands and over 100 products distributed in various countries. The company is headquartered in Stockholm and operates in several European countries, as well as in the United States and Canada. Karo Pharma emphasizes close collaboration with doctors and pharmacists to ensure that its products meet the needs of consumers optimally. In recent years, Karo Pharma has become the leading provider of over-the-counter drugs and health products in Scandinavia and now plans to expand its presence in other European countries. The company aims to strengthen its position as the leading provider of over-the-counter drugs and health products, with a focus on innovative and natural solutions, through a combination of organic growth and targeted acquisitions of companies with complementary products and technologies. Karo Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Karo Pharma's Liabilities
Karo Pharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Karo Pharma's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Karo Pharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Karo Pharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Karo Pharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Karo Pharma stock
What were the liabilities of Karo Pharma compared to the previous year?
The liabilities of Karo Pharma have increased by 0% dropped compared to the previous year.
What are the consequences of high debt for investors of Karo Pharma?
High liabilities can pose a risk for investors of Karo Pharma, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Karo Pharma?
Low liabilities mean that Karo Pharma has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Karo Pharma affect the company?
An increase in liabilities of Karo Pharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Karo Pharma affect the company?
A decrease in the liabilities of Karo Pharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Karo Pharma?
Some factors that can influence the liabilities of Karo Pharma include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Karo Pharma so important for investors?
The liabilities of Karo Pharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Karo Pharma take to modify the liabilities?
To change its liabilities, Karo Pharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Karo Pharma pay?
Over the past 12 months, Karo Pharma paid a dividend of 0.27 SEK . This corresponds to a dividend yield of about 0.45 %. For the coming 12 months, Karo Pharma is expected to pay a dividend of 0.4 SEK.
What is the dividend yield of Karo Pharma?
The current dividend yield of Karo Pharma is 0.45 %.
When does Karo Pharma pay dividends?
Karo Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Karo Pharma?
Karo Pharma paid dividends every year for the past 4 years.
What is the dividend of Karo Pharma?
For the upcoming 12 months, dividends amounting to 0.4 SEK are expected. This corresponds to a dividend yield of 0.66 %.
In which sector is Karo Pharma located?
Karo Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Karo Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Karo Pharma from 5/11/2018 amounting to 0.3 SEK, you needed to have the stock in your portfolio before the ex-date on 5/4/2018.
When did Karo Pharma pay the last dividend?
The last dividend was paid out on 5/11/2018.
What was the dividend of Karo Pharma in the year 2023?
In the year 2023, Karo Pharma distributed 0 SEK as dividends.
In which currency does Karo Pharma pay out the dividend?
The dividends of Karo Pharma are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Karo Pharma
Our stock analysis for Karo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
